Filana Therapeutics (FLNA) Capital Expenditures (2011 - 2025)

Filana Therapeutics has reported Capital Expenditures for 11 years, with the latest figure at $501000.0 in Q4 2025.

• On a quarterly basis, Capital Expenditures rose 778.95% year-over-year to $501000.0 in Q4 2025; TTM through Dec 2025 was $581000.0, a 464.08% increase from a year earlier, with the FY2025 full-year figure at $581000.0, up 464.08% from the prior year.
• Capital Expenditures was $501000.0 for Q4 2025 at Filana Therapeutics, up from $80000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $22.0 million in Q3 2021, with the low at -$335000.0 in Q4 2022.
• Average Capital Expenditures over 5 years is $1.7 million, with a median of $80000.0 recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures plunged 435.0% in 2022, then surged 778.95% in 2025.
• Over 5 years, Capital Expenditures stood at $100000.0 in 2021, then slumped by 435.0% to -$335000.0 in 2022, then soared by 112.24% to $41000.0 in 2023, then surged by 39.02% to $57000.0 in 2024, then soared by 778.95% to $501000.0 in 2025.
• The last three Capital Expenditures figures came in at $501000.0 (Q4 2025), $80000.0 (Q3 2025), and $57000.0 (Q4 2024), per Business Quant data.